Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
Status:
Active, not recruiting
Trial end date:
2022-06-11
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal
antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive
cancer. Diagnostic procedures, such as copper Cu 64 anti-CEA monoclonal antibody M5A PET, may
help find and diagnose CEA positive cancer that may not be detected by standard diagnostic
methods.